Regeneration

A new analysis that supports the effect of the diabetes vaccine Diamyd® will be presented at a scientific conference on 13 October

Thursday, September 23, 2021 - 4:08pm

The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.

Key Points: 
  • The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.
  • Complete results will be submitted for publication in a scientific journal later this year.
  • The diabetes vaccine Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production.
  • A vaccine manufacturing facility is being set up in Ume for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd.

A new analysis that supports the effect of the diabetes vaccine Diamyd® will be presented at a scientific conference on 13 October

Thursday, September 23, 2021 - 4:05pm

The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.

Key Points: 
  • The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.
  • Complete results will be submitted for publication in a scientific journal later this year.
  • The diabetes vaccine Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production.
  • A vaccine manufacturing facility is being set up in Ume for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd.

Galderma Announces Exclusive Agreement With Sofregen to Develop the Next Generation of Biostimulator Fillers Using Silk-Based Technology

Thursday, September 23, 2021 - 6:00am

This collaboration will further expand Galdermas capabilities built on decades of science-based aesthetics innovation and a unique heritage in biostimulator and hyaluronic acid (HA) fillers.

Key Points: 
  • This collaboration will further expand Galdermas capabilities built on decades of science-based aesthetics innovation and a unique heritage in biostimulator and hyaluronic acid (HA) fillers.
  • At Galderma, were committed to advancing dermatology through constant innovation and joining forces with other industry pioneers.
  • This agreement highlights Sofregens dedication to advancing the science of silk and will accelerate our ability to develop the next generation of biostimulator fillers with a recognized leader in this space.
  • Galderma will also have an exclusive option to acquire Sofregens Silk Voice as well as assets associated with its aesthetics business.

Dr. Carolin Barth Joins MiroBio as CEO to Lead Precision Immunology Company Focused on Checkpoint Agonist Antibodies

Tuesday, September 21, 2021 - 11:30am

Dr. Barth will lead MiroBio through the next major stage of its growth as its lead program, MB272, transitions into clinical development.

Key Points: 
  • Dr. Barth will lead MiroBio through the next major stage of its growth as its lead program, MB272, transitions into clinical development.
  • MiroBio is uniquely focused on a new area of precision immunology using checkpoint agonist antibodies.
  • A PD-1 agonist program, MB151, is also in preclinical development, followed by a growing pipeline of checkpoint agonist antibodies in earlier-stage development.
  • It is the ideal time for Carolin to assume leadership of MiroBio, saidEliot Charles, Ph.D, executive chairman of MiroBio.

Vicore obtains SARS coronavirus patent for C21 in the USA

Wednesday, September 22, 2021 - 7:26am

GOTHENBURG, Sweden, Sept. 22, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today announces that the U.S. Patent and Trademark Office (USPTO) has granted patent number US11,123,329 covering the use of C21 to treat infections caused by Severe Acute Respiratory Syndrome (SARS) coronavirus (CoV), including SARS-CoV-2.

Key Points: 
  • GOTHENBURG, Sweden, Sept. 22, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today announces that the U.S. Patent and Trademark Office (USPTO) has granted patent number US11,123,329 covering the use of C21 to treat infections caused by Severe Acute Respiratory Syndrome (SARS) coronavirus (CoV), including SARS-CoV-2.
  • "This C21/CoV patent gives Vicore patent protection in the US market until December 2040."
  • A major clinical impact of C21 on respiratory function in COVID-19 was documented in a recent phase 2 trial showing that C21 reduced the need for supplemental oxygen in hospitalized patients by 90%.
  • "The use of C21 to promote accelerated resolution of lung damage by SARS-CoV-2 and related conronaviruses is a promising and innovative therapeutic approach" said Johan Raud, CSO of Vicore.

Vicore obtains SARS coronavirus patent for C21 in the USA

Wednesday, September 22, 2021 - 7:25am

GOTHENBURG, Sweden, Sept. 22, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today announces that the U.S. Patent and Trademark Office (USPTO) has granted patent number US11,123,329 covering the use of C21 to treat infections caused by Severe Acute Respiratory Syndrome (SARS) coronavirus (CoV), including SARS-CoV-2.

Key Points: 
  • GOTHENBURG, Sweden, Sept. 22, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today announces that the U.S. Patent and Trademark Office (USPTO) has granted patent number US11,123,329 covering the use of C21 to treat infections caused by Severe Acute Respiratory Syndrome (SARS) coronavirus (CoV), including SARS-CoV-2.
  • "This C21/CoV patent gives Vicore patent protection in the US market until December 2040."
  • A major clinical impact of C21 on respiratory function in COVID-19 was documented in a recent phase 2 trial showing that C21 reduced the need for supplemental oxygen in hospitalized patients by 90%.
  • "The use of C21 to promote accelerated resolution of lung damage by SARS-CoV-2 and related conronaviruses is a promising and innovative therapeutic approach" said Johan Raud, CSO of Vicore.

Implant Success Rates Comparing Two Techniques

Tuesday, September 21, 2021 - 3:00pm

Specifically, implant success has improved because of the development of materials added to surgical sites when a tooth is removed.

Key Points: 
  • Specifically, implant success has improved because of the development of materials added to surgical sites when a tooth is removed.
  • Researchers and clinicians from Mansoura University and McGill University selected 14 patients who needed a tooth extraction and a dental implant.
  • They did find some significant differences in implant stability and PPD over time that were deemed as a possible result of the surgery techniques used.
  • The Journal of Oral Implantology is the official publication of the American Academy of Implant Dentistry and of the American Academy of Implant Prosthodontics.

ROKIT Healthcare Presented Successfully Regenerated Hyaline Cartilage at the 2021 American Academy of Orthopedic Surgeons (AAOS) event in San Diego

Thursday, September 16, 2021 - 1:00am

COSTA MESA, Calif., Sept. 15, 2021 /PRNewswire-PRWeb/ --Using 3D bioprinting technology, ROKIT Healthcare has proven their cartilage regeneration technology.

Key Points: 
  • COSTA MESA, Calif., Sept. 15, 2021 /PRNewswire-PRWeb/ --Using 3D bioprinting technology, ROKIT Healthcare has proven their cartilage regeneration technology.
  • This innovation in orthopedic intervention will soon help patients regrow knee cartilage and more.
  • ROKIT's hyaline cartilage regeneration technique has been tested globally on animals.
  • Dr. Charles Bragdon from Massachusetts General Hospital revealed successful regeneration of hyaline cartilage at the defect region where the patch was implanted.

Pew Funds Six Teams to Advance Innovative Biomedical Research

Wednesday, September 15, 2021 - 3:00pm

These scientistsalumni of Pew's biomedical programs in the United States and Latin Americawill partner on interdisciplinary research to tackle some of the most pressing questions in human biology and disease.

Key Points: 
  • These scientistsalumni of Pew's biomedical programs in the United States and Latin Americawill partner on interdisciplinary research to tackle some of the most pressing questions in human biology and disease.
  • "The COVID-19 pandemic has underscored the critical role innovative biomedical research plays in addressing global health problems," said Molly Irwin, vice president for research and science at The Pew Charitable Trusts.
  • For more than 35 years, Pew has encouraged collaboration among its diverse community of biomedical scientists, culminating in the launch of the Innovation Fund in 2017.
  • The fund's award criteria were developed to promote synergy among program alumni, motivating researchers to collaborate on new proposals.

ME2C® Environmental Completes Initial Testing of its Rare Earth Element Technology

Wednesday, September 15, 2021 - 1:31pm

CORSICANA, TX, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Midwest Energy Emissions Corp. (OTCQB: MEEC) ("ME2C Environmental" or the “Company”), a leading environmental technologies firm, announced today that Pennsylvania State University’s College of Earth and Mineral Sciences has completed the initial round of testing to evaluate the Company’s new Rare Earth Element (REE) Technology.

Key Points: 
  • CORSICANA, TX, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Midwest Energy Emissions Corp. (OTCQB: MEEC) ("ME2C Environmental" or the Company), a leading environmental technologies firm, announced today that Pennsylvania State Universitys College of Earth and Mineral Sciences has completed the initial round of testing to evaluate the Companys new Rare Earth Element (REE) Technology.
  • The initial results received by Penn States College of Earth and Mineral Sciences will lead to the further testing and development of this emerging technology focused on rare earth capture, as well as the cleanup of coal ash ponds and wastewater from coal-fired power plants, stated Richard MacPherson, CEO of ME2C Environmental.
  • ME2C Environmental (OTCQB: MEEC) is a leading environmental technologies company developing and delivering patented and proprietary solutions to the global power industry.
  • ME2C Environmental is a trade name of Midwest Energy Emissions Corp. For more information, please visit http://www.me2cenvironmental.com/ .